CalciMedica boosts ATM capacity to $9.7M from $4.45M

CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000.

Accepted by SEC EDGAR 11/06/2025 - 04:11 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000. The company filed a prospectus supplement to raise the maximum aggregate offering price of common stock that may be issued under its at‑the‑market offering agreement with H.C. Wainwright & Co.

The prior limit under the program was $4,450,000, as referenced in an earlier supplement. A legal opinion covering the $9,700,000 of common stock was included as Exhibit 5.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CALC announce in its 8-K?

CalciMedica filed a prospectus supplement increasing the maximum aggregate offering price under its at‑the‑market program to $9,700,000.

What was the previous ATM limit for CALC?

The prior maximum aggregate offering price was $4,450,000.

Who is CALC’s sales agent for the ATM?

The at‑the‑market offering agreement is with H.C. Wainwright & Co.

What document supports the increased ATM capacity?

A prospectus supplement was filed to effect the increase and an Exhibit 5.1 legal opinion was included.

What securities can be sold under the program?

Shares of common stock with a par value of $0.0001 per share.

When was the ATM agreement originally dated?

The at‑the‑market offering agreement is dated August 11, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASDAQ false 0001534133 0001534133 2025-11-06 2025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

CalciMedica, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39538		45-2120079
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

505 Coast Boulevard South, Suite 307
La Jolla, California		92037
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-5500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CALC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 6, 2025, CalciMedica, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “SEC”) to increase the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the Company’s at-the-market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., dated August 11, 2023, from $4,450,000 to $9,700,000. The Prospectus Supplement supplements the information in the prospectus dated August 18, 2023 (the “Prior Prospectus”), as previously supplemented by the prospectus supplement dated December 20, 2024, relating to the offer and sale of up to $4,450,000 of shares of the Common Stock pursuant to the Offering Agreement. A copy of the legal opinion as to the legality of the $9,700,000 of shares of Common Stock issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
5.1		Opinion of Cooley LLP
23.1		Consent of Cooley LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						CalciMedica, Inc.
Date: November 6, 2025				By:		/s/ A. Rachel Leheny, Ph. D.
				Name:		A. Rachel Leheny, Ph. D.
				Title:		Chief Executive Officer